Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Published:2018-03 Issue:3 Volume:5 Page:e109-e116
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Jerkeman Mats,Eskelund Christian Winther,Hutchings Martin,Räty Riikka,Wader Karin Fahl,Laurell Anna,Toldbod Helle,Pedersen Lone Bredo,Niemann Carsten Utoft,Dahl Christina,Kuitunen Hanne,Geisler Christian H,Grønbæk Kirsten,Kolstad Arne

Publisher

Elsevier BV

Subject

Hematology

Reference24 articles.

1. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dreyling;Ann Oncol,2017

2. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma;O'Connor;J Clin Oncol,2005

3. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma;Hess;J Clin Oncol,2009

4. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial;Trneny;Lancet Oncol,2016

5. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2013

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined targeting of Hedgehog/GLI1 and Wnt/β‐catenin pathways in mantle cell lymphoma;Hematological Oncology;2024-08-29

2. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions;Blood;2024-08-22

3. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma;New England Journal of Medicine;2024-06-20

5. Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review;Journal of Blood Medicine;2024-05